Ember LifeSciences secures Series A funding to advance temperature-controlled medicine storage
Key takeaways
- Ember LifeSciences recently secured $16.5 million in Series A funding.
- Cold chain failures cost pharma billions, creating demand for tighter temperature control in transport.
- The company's Ember Cube 2 supports high-volume, temp-sensitive shipments.
Ember LifeSciences recently secured $16.5 million in Series A funding led by Sea Court Capital, with participation from Cardinal Health, Carrier Ventures, and other investors. The company, which develops temperature control technology for pharmaceutical and healthcare distribution, plans to use the funding to advance product development and expand into global markets.
The investment will support Ember LifeSciences’ innovation pipeline, including the launch of Ember Cube 2, a next-generation version of its digital shipping box. Ember Cube 2 builds on data and operational insights from the first-generation Ember Cube and is designed to support organizations shipping high volumes of temperature-sensitive therapies.
The second-generation Ember Cube uses vacuum insulation and proprietary bio-based organic phase change material packs for thermal control. The platform is designed to scale across healthcare networks and support broader adoption throughout the supply chain, including patient-focused use cases.
The funding will also support higher-volume domestic deployments as Ember LifeSciences prepares to introduce products focused on medicine storage and transportation at the consumer level. Pharmaceutical distributors, specialty and infusion pharmacies, and testing laboratories, including CVS Health, Chartwell, and USADA, are adopting the company’s technology.
"Our breakthrough cold chain technology ensures life-saving medicines reach their destination safely, reliably, and sustainably," Clay Alexander, founder and CEO of Ember LifeSciences, said. "This investment marks a major step forward in advancing the future of healthcare, allowing us to accelerate our next-generation product development and expand into global markets."
